Company profile
SELLAS LIFE SCIENCES GROUP, INC.
NASDAQ:SLSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TAMBICICLIB | phase1_2 | — | 1 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01265433 | phase2 | completed | 2010-12-21 | 2016-11-30 | Sellas Life Sciences Group | Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy |
| NCT04229979 | phase3 | active_not_recruiting | 2021-02-08 | 2025-12-01 | Sellas Life Sciences Group | Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 |
| NCT03761914 | phase1_2 | completed | 2019-09-30 | 2022-07-05 | Sellas Life Sciences Group | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers |
| NCT04588922 | phase1_2 | recruiting | 2021-05-10 | 2026-12-30 | Sellas Life Sciences Group | Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML |
| NCT01827137 | phase1_2 | completed | 2013-04-01 | 2016-12-07 | Sellas Life Sciences Group | WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation |
FDA applications (0)
No records yet.